Bearish
Eli Lilly's stock price declines 1.2% amid competitor's drug setback
Eli Lilly's stock experienced a 1.2% decline following a competitor's drug setback. Novartis' cholesterol drug failed to reduce cardiovascular events, raising concerns about the efficacy of similar treatments, including Eli Lilly's.
Key points
- Novartis' cholesterol drug failed to reduce cardiovascular events, raising concerns about the efficacy of similar treatments, including Eli Lilly's.
- Eli Lilly's stock price declined 1.2% amid the news.
Sources
AI-generated from public news sources. Not financial advice.
